Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Current Liabilities: 2017-2024

Historic Total Current Liabilities for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $31.6 million.

  • Aclaris Therapeutics' Total Current Liabilities rose 36.22% to $25.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 million, marking a year-over-year increase of 36.22%. This contributed to the annual value of $31.6 million for FY2024, which is 2.08% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Total Current Liabilities stood at $31.6 million for FY2024, which was up 2.08% from $31.0 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Total Current Liabilities ranged from a high of $31.6 million in FY2024 and a low of $14.9 million during FY2020.
  • Over the past 3 years, Aclaris Therapeutics' median Total Current Liabilities value was $31.0 million (recorded in 2023), while the average stood at $28.2 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Total Current Liabilities tumbled by 33.69% in 2020, and later skyrocketed by 54.17% in 2021.
  • Over the past 5 years, Aclaris Therapeutics' Total Current Liabilities (Yearly) stood at $14.9 million in 2020, then soared by 54.17% to $22.9 million in 2021, then dropped by 4.33% to $21.9 million in 2022, then spiked by 41.09% to $31.0 million in 2023, then climbed by 2.08% to $31.6 million in 2024.